Article
Oncology
Nuala Helsby, Minghan Yong, Kathryn Burns, Michael Findlay, David Porter
Summary: The study aimed to assess the relationship between CP bioactivation with CYP2B6 and CYP2C19 genotype, as well as CYP2C19 phenotype, in breast cancer patients. Results showed a significant linear gene-dose relationship with CYP2B6 coding SNP and formation of 4-hydroxycyclophosphamide, while the phenotype of CYP2C19 may undergo substantial intra-individual change on subsequent dosing.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Yasmin Cura, Cristina Perez Ramirez, Almudena Sanchez Martin, Fernando Martinez Martinez, Miguel Angel Calleja Hernandez, Maria del Carmen Ramirez Tortosa, Alberto Jimenez Morales
Summary: Breast cancer treatment response varies due to genetic polymorphisms, with low-activity alleles associated with poorer outcomes and the need for clinical pharmacogenetic guidelines. Polymorphisms in genes are linked to treatment effectiveness and toxicity, potentially serving as future predictive genetic biomarkers. Further studies are needed to confirm and clarify the clinical relevance of these associations.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Bianza Tinotenda Mbavha, Roslyn Stella Thelingwani, Zedias Chikwambi, Anna Mary Nyakabau, Collen Masimirembwa
Summary: This study aimed to determine the association between CYP2D6 polymorphisms and endoxifen plasma concentrations in a cohort of Zimbabwean breast cancer patients (n = 40). The results showed that CYP2D6 phenotypes and activity scores were significantly associated with endoxifen plasma concentrations and endoxifen to N-desmethyl-tamoxifen ratios.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Chang Liu, Binglu Cheng, Gang Zhao, Hengjie Yuan
Summary: This study aimed to investigate the clinical adverse effects of anthracyclines on patients undergoing chemotherapy after breast cancer surgery. The results showed that in the early stage of chemotherapy, heart rate and triglycerides increased significantly, while hemoglobin and albumin decreased. ST-segment abnormalities increased during the entire chemotherapy period, and creatine kinase and lactate dehydrogenase increased significantly in the late stage of chemotherapy. High-density lipoprotein decreased throughout the chemotherapy period. In anthracycline chemotherapy regimens, bone marrow suppression and dyslipidemia occur in the early stage of chemotherapy, and the risk of cardiotoxicity is higher in the late stage of chemotherapy.
JOURNAL OF INVESTIGATIVE MEDICINE
(2022)
Article
Genetics & Heredity
Andrew R. Marderstein, Scott Kulm, Cheng Peng, Rulla Tamimi, Andrew G. Clark, Olivier Elemento
Summary: The study reveals that genetic risk of breast cancer can explain nearly three times greater variation in disease risk within corticosteroid users compared to non-users, with 35 genes significantly interacting with corticosteroid use and a regulatory variant strongly stratifying breast cancer risk according to corticosteroid use.
AMERICAN JOURNAL OF HUMAN GENETICS
(2021)
Article
Oncology
Aline Hajj, Rami Chamoun, Pascale Salameh, Rita Khoury, Roula Hachem, Hala Sacre, Georges Chahine, Joseph Kattan, Lydia Rabbaa Khabbaz
Summary: This study assessed the severity of cancer-related fatigue in a group of breast cancer patients undergoing chemotherapy and explored the association between fatigue scores and various factors. The results showed that a higher number of chemotherapy cycles, lower hemoglobin levels, and specific gene polymorphisms were significantly associated with increased odds of experiencing fatigue. Future studies are needed to confirm these genetic findings.
Review
Oncology
Tessa A. M. Mulder, Miriam de With, Marzia del Re, Romano Danesi, Ron H. J. Mathijssen, Ron H. N. van Schaik
Summary: Tamoxifen is a crucial adjuvant endocrine therapy for estrogen receptor (ER)-positive breast cancer patients, with the conversion to the active metabolite endoxifen mainly depending on the CYP2D6 enzyme. Genetic variations in the CYP2D6 gene can impact endoxifen formation and therapy outcomes, though the correlation between CYP2D6 genotype and clinical outcome remains debated. Recent developments from 2018 to 2020 shed light on this ongoing debate.
Review
Biochemistry & Molecular Biology
Nasim Vahidfar, Ayuob Aghanejad, Hojjat Ahmadzadehfar, Saeed Farzanehfar, Elisabeth Eppard
Summary: The concept of 'theranostic' involves using the same radioligand to target an identical receptor for diagnostic and therapeutic purposes. Many significant theranostic tracers have been developed in recent years, showing the direction of nuclear medicine towards therapies based on diagnosis. This review focuses on targeted radiopharmaceuticals for imaging and therapy of breast cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Aline Hajj, Roula Hachem, Rita Khoury, Souheil Hallit, Bashar ElJebbawi, Fady Nasr, Fadi El Karak, Georges Chahine, Joseph Kattan, Lydia Rabbaa Khabbaz
Summary: The study aimed to evaluate the level of anxiety and depression among breast cancer patients receiving chemotherapy, and found that cognitive impairment, sleep quality, marital status, specific gene polymorphisms, and medication intake were correlated with these psychological disorders.
Article
Oncology
Jose Pablo Leone, Michael J. Hassett, Julieta Leone, Sara M. Tolaney, Carlos T. Vallejo, Bernardo A. Leone, Eric P. Winer, Nancy U. Lin
Summary: This study compares the proportions of pathologic complete response (pCR) between male breast cancer (MaBC) and female breast cancer (FBC) in neoadjuvant chemotherapy (NAC), and finds that FBC has higher pCR rates. Furthermore, pCR is associated with survival rates in both MaBC and FBC.
Article
Oncology
Christopher J. Gibson, Geoffrey Fell, Tal Sella, Adam S. Sperling, Craig Snow, Shoshana M. Rosenberg, Greg Kirkner, Ashka Patel, Deborah Dillon, Alexander G. Bick, Donna Neuberg, Ann H. Partridge, Peter G. Miller
Summary: This study aimed to investigate the presence of clonal hematopoiesis of indeterminate potential (CHIP) in young women treated for breast cancer and its impact on prognosis. The results showed that only a small number of patients had clones large enough to be diagnosed as CHIP, and there was no significant association between their prognosis and non-breast cancer-related outcomes.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Pierre Loap, Ludovic De Marzi, Carlos Eduardo Almeida, Amelia Barcellini, Julie Bradley, Maria Carmen de Santis, Remi Dendale, Rachel Jimenez, Ester Orlandi, Youlia Kirova
Summary: Radiotherapy plays a crucial role in breast cancer treatment, and Hadrontherapy techniques have potential for improving therapeutic outcomes by limiting side effects and enhancing tumor control.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Medicine, General & Internal
Timothy J. Whelan, Sally Smith, Sameer Parpia, Anthony W. Fyles, Anita Bane, Fei-Fei Liu, Eileen Rakovitch, Lynn Chang, Christiaan Stevens, Julie Bowen, Sawyna Provencher, Valerie Theberge, Anna Marie Mulligan, Zuzana Kos, Mohamed A. Akra, K. David Voduc, Tarek Hijal, Ian S. Dayes, Gregory Pond, James R. Wright, Torsten O. Nielsen, Mark N. Levine
Summary: Among women with T1N0 grade 1 or 2 luminal A breast cancer who had undergone breast-conserving surgery and received endocrine therapy, the incidence of local recurrence at 5 years was low without radiotherapy.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Chemistry, Medicinal
Tingting Liu, Shubin Song, Xu Wang, Jifu Hao
Summary: Breast cancer remains a challenging health issue and a top priority in biomedical research. Researchers are increasingly interested in studying breast cancer in young women. Common treatment options for breast cancer include chemotherapy, immunotherapy, hormone therapy, surgery, and radiotherapy.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Oncology
Giuseppe Curigliano, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frederique Penault-Llorca, Aleix Prat
Summary: Breast cancer multigene signatures (BCMS) have changed the management of early-stage breast cancer (eBC) by providing prognostic information and helping select patients for adjuvant chemotherapy. However, there is limited knowledge on the current usage and perceived utility of BCMS in clinical practice. A two-round Delphi survey involving 133 breast cancer experts from 11 European countries revealed that BCMS are widely used to assess risk of recurrence and select patients for adjuvant chemotherapy, but consensus is lacking regarding their utility in selecting specific chemotherapy types. There are also discrepancies between recommended usage and actual usage, with some profiles lacking supporting evidence. The study suggests the need for physician education initiatives to ensure proper use and interpretation of BCMS, ultimately improving management of eBC patients.
Article
Oncology
Ning-Yuan Lee, Melissa Hum, Pei-Yi Ong, Matthew Khine Myint, Enya H. W. Ong, Kar-Perng Low, Zheng Li, Boon-Cher Goh, Joshua K. Tay, Kwok-Seng Loh, Melvin L. K. Chua, Soo-Chin Lee, Chiea-Chuen Khor, Ann S. G. Lee
Summary: This study aimed to identify germline genetic variants associated with an increased risk of developing nasopharyngeal carcinoma (NPC). Through sequencing DNA samples from Singaporean NPC patients, the study found 17 pathogenic variants enriched in NPC patients as compared to unaffected controls. Five of these variants were supported by repeated testing on an independent set of Singaporean NPC patients and controls. The study also identified the association between specific genes (JAK2, PRDM16, LRP1B, NIN, and NKX2-1) and NPC risk. Pathway analysis revealed a higher frequency of germline mutations in endocytosis and immune-modulating pathways. Overall, this research provides important insights into the genetic predisposition of NPC.
Article
Biochemistry & Molecular Biology
Chieh Yang Koo, Huili Zheng, Li Ling Tan, Ling-Li Foo, Derek J. Hausenloy, Wee-Joo Chng, Soo Chin Lee, Arthur Mark Richards, Lieng-Hsi Ling, Shir Lynn Lim, Chi-Hang Lee, Mark Y. Chan
Summary: Patients with prior cancer have lower ASCVD risk at incident AMI compared to those without cancer, but they receive lower guideline-directed medical therapy post-AMI and have higher mortality.
Meeting Abstract
Hematology
Joanne Lee, Hossein Tabatabaeian, Michelle Limei Poon, Nagavalli Somasundaram, Liu Xin, Yi Ching Yuen, Chia Meng Teoh, Benedict Yan, Esther Hian Li Chan, Yen Lin Chee, Sanjay De Mel, Bin Zhang, Xiao Hong Chew, Tiffany Tang, Chiea Chuen Khor, Joanne Yuen Yie Ngeow, Choon Kiat Ong, Soon Thye Lim, Wee Joo Chng, E. Shyong Tai, Kee Yuan Ngiam, Soo Chin Lee, Boon Cher Goh, Anand Devaprasath D. Jeyasekharan, Yvonne Tay, Folefac Aminkeng
Article
Medicine, Research & Experimental
Win Lwin Thuya, Li Ren Kong, Nicholas L. Syn, Ling -Wen Ding, Esther Sok Hwee Cheow, Regina Tong Xin Wong, Tingting Wang, Robby Miguel Wen-Jing Goh, Hongyan Song, Migara K. Jayasinghe, Minh T. N. Le, Jian Cheng Hu, Wei-Peng Yong, Soo-Chin Lee, Andrea Li-Ann Wong, Gautam Sethi, Huynh The Hung, Paul Chi-Lui Ho, Jean-Paul Thiery, Siu Kwan Sze, Tiannan Guo, Ross A. Soo, Henry Yang, Yaw Chyn Lim, Lingzhi Wang, Boon-Cher Goh
Summary: This study reveals that the cargo protein FAM3C carried by tumor-released extracellular vesicles (EVs) can enhance the growth and metastatic potential of lung cancer cells. FAM3C interacts with RalA protein to activate the Src/Stat3 signaling pathway, promoting oncogenicity. This finding provides a new target for lung cancer therapy.
Article
Oncology
Jerold Loh, Jiaxuan Wu, Jenny Chieng, Aurora Chan, Wei-Peng Yong, Raghav Sundar, Soo-Chin Lee, Andrea Wong, Joline S. J. Lim, David S. P. Tan, Ross Soo, Boon-Cher Goh, Bee-Choo Tai, Cheng E. Chee
Summary: Patient selection is crucial in Phase I studies, particularly in heavily pre-treated patients where prognosis estimation is challenging. Existing prognostic models like the Royal Marsden Hospital (RMH) score or the neutrophil-lymphocyte ratio (NLR) have not been validated in current novel therapies or in the Asian Phase I population.
BRITISH JOURNAL OF CANCER
(2023)
Correction
Genetics & Heredity
Ceres Fernandez-Rozadilla, Maria Timofeeva, Zhishan Chen, Philip Law, Minta Thomas, Stephanie Schmit, Virginia Diez-Obrero, Li Hsu, Juan Fernandez-Tajes, Claire Palles, Kitty Sherwood, Sarah Briggs, Victoria Svinti, Kevin Donnelly, Susan Farrington, James Blackmur, Peter Vaughan-Shaw, Xiao-ou Shu, Jirong Long, Qiuyin Cai, Xingyi Guo, Yingchang Lu, Peter Broderick, James Studd, Jeroen Huyghe, Tabitha Harrison, David Conti, Christopher Dampier, Mathew Devall, Fredrick Schumacher, Marilena Melas, Gad Rennert, Mireia Obon-Santacana, Vicente Martin-Sanchez, Ferran Moratalla-Navarro, Jae Hwan Oh, Jeongseon Kim, Sun Ha Jee, Keum Ji Jung, Sun-Seog Kweon, Min-Ho Shin, Aesun Shin, Yoon-Ok Ahn, Dong-Hyun Kim, Isao Oze, Wanqing Wen, Keitaro Matsuo, Koichi Matsuda, Chizu Tanikawa, Zefang Ren, Yu-Tang Gao, Wei-Hua Jia, John Hopper, Mark Jenkins, Aung Ko Win, Rish Pai, Jane Figueiredo, Robert Haile, Steven Gallinger, Michael Woods, Polly Newcomb, David Duggan, Jeremy Cheadle, Richard Kaplan, Timothy Maughan, Rachel Kerr, David Kerr, Iva Kirac, Jan Bohm, Lukka-Pekka Mecklin, Pekka Jousilahti, Paul Knekt, Lauri Aaltonen, Harri Rissanen, Eero Pukkala, Johan Eriksson, Tatiana Cajuso, Ulrika Hanninen, Johanna Kondelin, Kimmo Palin, Tomas Tanskanen, Laura Renkonen-Sinisalo, Brent Zanke, Satu Mannisto, Demetrius Albanes, Stephanie Weinstein, Edward Ruiz-Narvaez, Julie Palmer, Daniel Buchanan, Elizabeth Platz, Kala Visvanathan, Cornelia Ulrich, Erin Siegel, Stefanie Brezina, Andrea Gsur, Peter Campbell, Jenny Chang-Claude, Michael Hoffmeister, Hermann Brenner, Martha Slattery, John Potter, Konstantinos Tsilidis, Matthias Schulze, Marc Gunter, Neil Murphy, Antoni Castells, Sergi Castellvi-Bel, Leticia Moreira, Volker Arndt, Anna Shcherbina, Mariana Stern, Bens Pardamean, Timothy Bishop, Graham Giles, Melissa Southey, Gregory Idos, Kevin McDonnell, Zomoroda Abu-Ful, Joel Greenson, Katerina Shulman, Flavio Lejbkowicz, Kenneth Offit, Yu-Ru Su, Robert Steinfelder, Temitope Keku, Bethany van Guelpen, Thomas Hudson, Heather Hampel, Rachel Pearlman, Sonja Berndt, Richard Hayes, Marie Elena Martinez, Sushma Thomas, Douglas Corley, Paul Pharoah, Susanna Larsson, Yun Yen, Heinz-Josef Lenz, Emily White, Li Li, Kimberly Doheny, Elizabeth Pugh, Tameka Shelford, Andrew Chan, Marcia Cruz-Correa, Annika Lindblom, David Hunter, Amit Joshi, Clemens Schafmayer, Peter Scacheri, Anshul Kundaje, Deborah Nickerson, Robert Schoen, Jochen Hampe, Zsofia Stadler, Pavel Vodicka, Ludmila Vodickova, Veronika Vymetalkova, Nickolas Papadopoulos, Chistopher Edlund, William Gauderman, Duncan Thomas, David Shibata, Amanda Toland, Sanford Markowitz, Andre Kim, Stephen Chanock, Franzel van Duijnhoven, Edith Feskens, Lori Sakoda, Manuela Gago-Dominguez, Alicja Wolk, Alessio Naccarati, Barbara Pardini, Liesel FitzGerald, Soo Chin Lee, Shuji Ogino, Stephanie Bien, Charles Kooperberg, Christopher Li, Yi Lin, Ross Prentice, Conghui Qu, Stephane Bezieau, Catherine Tangen, Elaine Mardis, Taiki Yamaji, Norie Sawada, Motoki Iwasaki, Christopher Haiman, Loic Le Marchand, Anna Wu, Chenxu Qu, Caroline McNeil, Gerhard Coetzee, Caroline Hayward, Ian Deary, Sarah Harris, Evropi Theodoratou, Stuart Reid, Marion Walker, Li Yin Ooi, Victor Moreno, Graham Casey, Stephen Gruber, Ian Tomlinson, Wei Zheng, Malcolm Dunlop, Richard Houlston, Ulrike Peters
Article
Oncology
Cheng E. Chee, Melissa Ooi, Soo-Chin Lee, Raghav Sundar, Valerie Heong, Wei-Peng Yong, Chin Hin Ng, Andrea Wong, Joline S. J. Lim, David S. P. Tan, Ross Soo, Joshua T. C. Tan, Song Yang, Min Thura, Abdul Qader Al-Aidaroos, Wee Joo Chng, Qi Zeng, Boon-Cher Goh
Summary: This study aims to evaluate the safety and efficacy of PRL3-zumab in patients with advanced solid tumors and hematological malignancies. The results show that PRL3-zumab is safe and tolerable, with stable disease observed in some solid tumor patients.
Article
Oncology
Jia Li Low, Elaine Lim, Lavina Bharwani, Andrea Wong, Karmen Wong, Samuel Ow, Siew Eng Lim, Matilda Lee, Joan Choo, Joline Lim, Gloria Chan, Robert John Walsh, Vaishnavi Muthu, Natalie Ngoi, Wanqin Chong, Sing Huang Tan, Soo Chin Lee
Summary: This study evaluates the efficacy and toxicity of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in real-world settings. The results show that CDK4/6i is safe and effective in the treatment of breast cancer. Age >70, distant metastases to liver, peritoneum or brain are negative prognostic factors. Patients over the age of 70 are more likely to require dose modifications.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Oncology
Jia Li Low, Yiqing Huang, Kenneth Sooi, Zhi Yao Chan, Wei Peng Yong, Soo Chin Lee, Boon Cher Goh
Summary: The rising cost of oncological drugs is a global challenge. Attenuated dose immune checkpoint inhibitors (ICIs) offer a cost-effective strategy, and this study provides evidence of their effectiveness and economic impact in the treatment of non-small cell lung cancer (NSCLC).
FRONTIERS IN ONCOLOGY
(2022)
Correction
Genetics & Heredity
Ning Yuan Lee, Melissa Hum, Aseervatham Anusha Amali, Wei Kiat Lim, Matthew Wong, Matthew Khine Myint, Ru Jin Tay, Pei-Yi Ong, Jens Samol, Chia Wei Lim, Peter Ang, Min-Han Tan, Soo-Chin Lee, Ann S. G. Lee
Article
Genetics & Heredity
Ning Yuan Lee, Melissa Hum, Aseervatham Anusha Amali, Wei Kiat Lim, Matthew Wong, Matthew Khine Myint, Ru Jin Tay, Pei-Yi Ong, Jens Samol, Chia Wei Lim, Peter Ang, Min-Han Tan, Soo-Chin Lee, Ann S. G. Lee
Summary: Novel germline variants associated with breast cancer predisposition were identified through whole-exome sequencing. Case-control analysis and comparison with multiple databases confirmed 14 variants consistently enriched in breast cancer cases.
Meeting Abstract
Oncology
Gwo Fuang Ho, Soo-Chin Lee, Joanna Lim, Anita Zarina Bustam, Siew Eng Lim, Marniza Saad, Samuel Guan Wei Ow, Natalie Ngoi, Nur Fadhlina Abdul Satar, Rozita Abdul Malik, Adlinda Alip, Kian Boon Law, Yok Yong Toh, Jia Wern Pan, Soo Hwang Teo
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Joan R. E. Choo, Yi-Hua Jan, Samuel G. W. Ow, Andrea Wong, Matilda Xinwei Lee, Natalie Ngoi, Kritika Yadav, Joline S. J. Lim, Siew Eng Lim, Ching Wan Chan, Mikael Hartman, Siau Wei Tang, Boon Cher Goh, Hon Lyn Tan, Wan Qin Chong, Ang Li En Yvonne, Gloria H. J. Chan, Shu-Jen Chen, Kien Thiam Tan, Soo Chin Lee
Summary: Serial molecular profiling can identify early therapy-induced genomic alterations in HER2-negative breast cancer patients, which may guide the selection of targeted therapies in patients who progress after standard chemotherapy.
Article
Oncology
Jerold Loh, Pei Yi Ong, Denise Li Meng Goh, Mark E. Puhaindran, Balamurugan A. Vellayappan, Samuel Guan Wei Ow, Gloria Chan, Soo-Chin Lee
Summary: Hereditary peripheral nerve sheath tumors (PNSTs) are uncommon in the general population. Through analyzing the clinical characteristics and genetic testing results, NF1 is found to be the most common PNST, and LZTR1 variants may be the underlying cause in Asian patients with multiple schwannomatosis.
HEREDITARY CANCER IN CLINICAL PRACTICE
(2022)
Article
Oncology
Jingshan Ho, Valerie Heong, Wei Peng Yong, Ross Soo, Cheng Ean Chee, Andrea Wong, Raghav Sundar, Yee Liang Thian, Anil Gopinathan, Mei Yan Pang, Priscillia Koe, Santhiay Nathan Jeraj, Phyu Pyar Soe, Mu Yar Soe, Tiffany Tang, Matthew C. H. Ng, David W. M. Tai, Tira J. Y. Tan, Hongmei Xu, Hua Chang, Yosef Landesman, Jatin Shah, Sharon Shacham, Soo Chin Lee, Daniel S. W. Tan, Boon Cher Goh, David S. P. Tan
Summary: This phase 1 study evaluated the tolerability and recommended dose of Selinexor in Asian patients with advanced malignancies. The results showed that a dose of 40 mg/m^2 given twice every 3 weeks was the most tolerable for Asian patients. Selinexor had rapid oral absorption and no PK accumulation.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)